Celltrion outlines big plans for subcutaneous infliximab in 2019

10 January 2019
celltrion-big

At the JP Morgan Healthcare Conference in San Francisco, South Korea’s Celltrion (Kosdaq: 068270) outlined details of its business plan for 2019, confirming the firm’s main focus will be on the development of a subcutaneous form of CT-P13, a biosimilar version of the immunological therapy infliximab.

Developed by Johnson & Johnson (NYSE: JNJ), the reference version of infliximab is marketed as Remicade.

A subcutaneous version would give people the opportunity to self-inject, allowing them to receive treatment at home.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biosimilars